ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Lack of Efficacy of Eculizumab for Prevention of Delayed Graft Function (DGF) in Deceased Donor Kidney Transplant Recipients

P. Heeger,1 E. Akalin,2 M. Baweja,1 R. Bloom,3 S. Florman,1 B. Haydel,1 D. Hricik,4 S. Kulkarni,5 A. Mehrotra,1 A. Patel,6 E. Poggio,7 L. Ratner,8 S. Schröppel,1 R. Shapiro.1

1Mount Sinai Hosp, NY, NY
2Montefiore Hosp, NY, NY
3Hosp U Pa, Phila, PA
4U Hosp Cleveland, Cleveland, OH
5Yale U Hosp, New Haven, CT
6St Barnabas Med Ctr, Livingston, NJ
7Cleveland Clinic, Cleveland, OH
8Columbia-Presbyterian Hosp, NY, NY.

Meeting: 2018 American Transplant Congress

Abstract number: B131

Keywords: Donors, Graft function, Immunosuppression, unrelated

Session Information

Session Name: Poster Session B: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Sunday, June 3, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

DGF portends poor short- and long-term renal function, increases cost, and may reduce graft survival. We studied the safety/efficacy of eculizumab (ECU), a C5 convertase inhibitor, in 2 related, investigator sponsored trials with funding provided by Alexion. 27 crossmatch- and DSA-neg recipients (8 from Sinai in 1st, 19 from 8 sites in 2nd) were enrolled (of 68 planned). Enrollment criteria were similar in the 2 studies including: ECD kidneys with brain death (kidney donors ≥60 y or age 50-59 and 2 of the following 3: hypertension, terminal serum cre >1.5 mg/dl, or death from CVA), or SCD kidneys with actual cold ischemic time (CIT) of 18-40 h. Recipients received meningococcal vaccine prior to transplantation. Patients received ATG followed by standard dose TAC, MMF and steroids and were randomized to receive 1200 mg ECU (n=16) or saline (n=11), with infusion initiated prior to organ reperfusion in the OR. In the 2nd study, a 2nd 900 mg dose of ECU was administered 12-24 h after the initial dose. The primary endpoint was the incidence of DGF defined as need for dialysis within the first week (excluding hyperkalemia or vol. overload in 1st 8 patients). Combined data analysis show the median age of 58 y, 17/27 male, 12/27 African American, and 15/27 with type II DM. There were no epidemiological or immunological differences btw groups. CIT was 22.6 (control) vs 23.8 h (ECU, p=ns). ECU was well tolerated with similar severe adverse event (SAE) rates; 2 ECU patients and no controls experienced infectious SAE (wound, UTI). There were no meningo/pneumococcal infections. Incidence of DGF was 5/11 (45%) controls vs 7/16 (44%) ECU (p=ns). Urine output on d1 and 7 did not differ, nor did the rate of reduction of serum Cre d 0-7. The study was halted prior to completing enrollment because results of a randomized trial of 286 patients performed independently by Alexion with similar design showed no efficacy for ECU in preventing DGF. Our findings do not support intraoperative, pre-reperfusion ECU to prevent DGF in deceased donor kidney transplantation.

CITATION INFORMATION: Heeger P., Akalin E., Baweja M., Bloom R., Florman S., Haydel B., Hricik D., Kulkarni S., Mehrotra A., Patel A., Poggio E., Ratner L., Schröppel S., Shapiro R. Lack of Efficacy of Eculizumab for Prevention of Delayed Graft Function (DGF) in Deceased Donor Kidney Transplant Recipients Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Heeger P, Akalin E, Baweja M, Bloom R, Florman S, Haydel B, Hricik D, Kulkarni S, Mehrotra A, Patel A, Poggio E, Ratner L, Schröppel S, Shapiro R. Lack of Efficacy of Eculizumab for Prevention of Delayed Graft Function (DGF) in Deceased Donor Kidney Transplant Recipients [abstract]. https://atcmeetingabstracts.com/abstract/lack-of-efficacy-of-eculizumab-for-prevention-of-delayed-graft-function-dgf-in-deceased-donor-kidney-transplant-recipients/. Accessed June 2, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences